After Novartis AG (NVS) Scandal, Japan Considers Penalties for False Data
8/6/2013 6:59:17 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
The government is considering new legislation to regulate clinical studies, in the wake of revelations of data falsification in clinical studies for a high blood pressure medicine. Prompted by recent allegations involving the drug Diovan, produced by Novartis Pharma K.K., the government is discussing establishing the new law to prevent recurrence of similar problems. It is expected to oblige researchers in clinical studies to preserve medical records and other data and submit them to the government.
Help employers find you! Check out all the jobs and post your resume.
comments powered by